Oral composition
Patent Information
- Application Number
- MYPI2025002021
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-03
- Filing Date
- 2023-10-02
- Publication Date
- 2024-04-03
AI Technical Summary
Chlorogenic acids in coffee beans, when roasted, lose potency and cause an astringent taste due to decomposition, making it difficult to maintain their physiological benefits and palatability in beverages.
An oral composition containing chlorogenic acids, caffeine, and 4-vinylguaiacol in specific mass ratios, along with lactone, to suppress astringency and enhance the physiological effects of chlorogenic acids.
The composition effectively suppresses astringency and enhances the physiological benefits of chlorogenic acids, improving the taste and efficacy of chlorogenic acids in beverages.
Abstract
Description
Oral Composition
[0001] The present invention relates to oral compositions.
[0002] Chlorogenic acids are a type of polyphenol and have been reported to have physiological effects such as antioxidant and antihypertensive properties. Coffee beans are known to be a source of high levels of chlorogenic acids. As coffee beans are roasted to a higher degree, their aroma becomes richer and more palatable. However, as the roasting level increases, a significant amount of the chlorogenic acids present in the coffee beans decomposes. Therefore, to maximize the utilization of chlorogenic acids, it is advantageous to use chlorogenic acid reagents or low-roasted or unroasted coffee beans as raw materials. However, when these are used as raw materials, the strong bitterness derived from chlorogenic acids can be a hindrance to continuous intake. One known technique for suppressing the bitterness derived from chlorogenic acids is to incorporate 4-vinylguaiacol at a specific mass ratio relative to chlorogenic acids (Patent Document 1).
[0003] As a technology for improving the taste of beverages, it has been reported that, for example, in low-acid, caffeine-containing beverages, the bitterness of caffeine can be suppressed by adding a certain amount of β-damascenone and guaiacol (Patent Document 2).Furthermore, it has also been reported that the body of a packaged coffee beverage can be enhanced by adding water to roasted coffee beans, heating them to vaporize them, and concentrating and recovering the vaporized fraction containing furfuryl alcohol and γ-butyrolactone (Patent Document 3).
[0004] (Patent Document 1) JP 2022-65462 A (Patent Document 2) JP 2019-213512 A (Patent Document 3) WO 2010 / 147222
[0005] The present invention provides the following [1] to
[12] . [1] A composition containing the following components (A), (B), and (C): (A) 5 to 20% by mass of chlorogenic acids, (B) 0.001% by mass or more and less than 0.4% by mass of caffeine, and (C) 4-vinylguaiacol, wherein the mass ratio of component (B) to component (C) [(C) / (B)] is 3×10-4 Above 1100 x 10 -4 [2] A composition for oral administration, wherein the mass ratio of component (A) to component (C) [(C) / (A)] is 1 x 10 -6 300 x 10 or more -6 [3] The composition for oral administration according to the above [1], wherein the mass ratio of component (A) to component (B) [(B) / (A)] is 1 x 10 -4 Above 500 x 10 -4 The oral composition according to [1] or [2] above, wherein the content of component (C) is 0.1 to 60 mass ppm. [4] The oral composition according to any one of [1] to [3] above, wherein the content of component (C) is 0.1 to 60 mass ppm. [5] The oral composition according to any one of [1] to [4] above, further comprising a lactone as component (D). [6] The oral composition according to [5] above, wherein component (D) comprises γ-butyrolactone. [7] The mass ratio of component (B) to component (D) [(D) / (B)] is 3 x 10 -4 Above 1200 x 10 -4 [8] The oral composition according to any one of [5] to [7] above, wherein the mass ratio of component (C) to component (D) [(D) / (C)] is 0.1 to 50. [9] The oral composition according to any one of [1] to [8] above, which is a solid oral composition.
[10] The oral composition according to any one of [1] to [8] above, which is a liquid oral composition.
[11] An astringency suppressant for oral products containing (C) 4-vinylguaiacol as an active ingredient, and the following components (A) and (B): (A) 5 to 20% by mass of chlorogenic acids, and (B) 0.001% by mass or more but less than 0.4% by mass of caffeine, wherein the mass ratio of (C) 4-vinylguaiacol to (B) caffeine [(C) / (B)] is 3 x 10 -4 Above 1100 x 10 -4
[12] A method for suppressing the astringency of an oral product containing the following components (A) and (B): (A) 5 to 20% by mass of chlorogenic acids, and (B) 0.001% by mass or more but less than 0.4% by mass of caffeine, wherein (C) 4-vinylguaiacol is present in an amount of 3 x 10 in a mass ratio [(C) / (B)] to (B) caffeine.-4 Above 1100 x 10 -4 A method for suppressing astringency by coexisting the ingredients in the following proportions. Detailed Description of the Invention
[0006] The present inventors have conducted research to develop an oral composition using chlorogenic acid reagents or lightly roasted or unroasted coffee beans as raw materials, with the aim of enhancing the physiological effects of chlorogenic acids. They discovered that adding caffeine to high-concentration chlorogenic acids results in different taste profiles depending on the caffeine content. Specifically, the present inventors discovered that adding trace amounts of caffeine to high-concentration chlorogenic acids results in a perceived astringent taste. The present invention relates to an oral composition with reduced astringency.
[0007] In view of the above problems, the present inventors have conducted extensive research and found that the astringency of an oral composition containing a high concentration of chlorogenic acids and a trace amount of caffeine can be suppressed by incorporating 4-vinylguaiacol in a specific mass ratio relative to caffeine. Furthermore, the present inventors have found that the astringency suppression effect can be enhanced by incorporating 4-vinylguaiacol in combination with a lactone.
[0008] According to the present invention, an oral composition with reduced astringency can be provided.
[0009] [Oral Composition] The oral composition of the present invention contains chlorogenic acids as component (A). Herein, "chlorogenic acids" is a collective term for monocaffeoylquinic acids, i.e., 3-caffeoylquinic acid, 4-caffeoylquinic acid, and 5-caffeoylquinic acid; monoferulic acids, i.e., 3-ferulic acid, 4-ferulic acid, and 5-ferulic acid; and dicaffeoylquinic acids, i.e., 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid. In the present invention, at least one of the nine types listed above may be contained. Component (A) may be in the form of a salt or hydrate. The salt is not particularly limited as long as it is physiologically acceptable, and examples thereof include alkali metal salts.
[0010] The origin of component (A) is not particularly limited as long as it is commonly used in the food and beverage industry, and it may be, for example, a chemically synthesized product or a product derived from a natural product. Examples of natural products include plant extracts. The plants used for extraction are not particularly limited as long as they contain component (A), and examples include sunflower seeds, unripe apples, coffee beans, Simon leaves, pine cones, pine seed shells, sugarcane, nandina leaves, burdock, eggplant skin, plum fruit, coltsfoot, and Vitaceae plants. One or more types of plants can be used. The extraction method and extraction conditions for the plant extract are not particularly limited, and known methods can be used. The plant extract may be concentrated or dried, and may be purified to increase the purity of chlorogenic acids. Known methods may be used for concentration, drying, and purification.
[0011] The content of component (A) in the oral composition of the present invention is 5 to 20% by mass. From the viewpoint of enhancing the physiological effects of component (A), it is preferably 6% by mass or more, more preferably 6.5% by mass or more, and even more preferably 7% by mass or more. From the viewpoint of suppressing astringency, it is preferably 18% by mass or less, more preferably 17% by mass or less, and even more preferably 16% by mass or less. The content of component (A) in the oral composition of the present invention is preferably 6 to 18% by mass, more preferably 6.5 to 17% by mass, and even more preferably 7 to 16% by mass. Herein, the content of component (A) is defined based on the total amount of the above nine components. When component (A) is in the form of a salt or hydrate, the content of component (A) is expressed as a value converted to the free acid chlorogenic acids. The content of component (A) can be measured by a commonly known analytical method appropriate to the conditions of the measurement sample, for example, liquid chromatography. Specific examples include the methods described in the Examples below. During measurement, the sample may be freeze-dried to fit the detection range of the instrument, or impurities may be removed from the sample to fit the resolution of the instrument, or other appropriate treatments may be performed as needed.
[0012] The oral composition of the present invention contains caffeine as component (B). Component (B) may be derived from the raw material or may be newly added.
[0013] The content of component (B) in the oral composition of the present invention is from 0.001% by mass to less than 0.4% by mass. From the viewpoint of the range in which the effects of the present invention can be easily enjoyed, it is preferably 0.005% by mass or more, more preferably 0.03% by mass or more, and even more preferably 0.05% by mass or more. From the same viewpoint, it is preferably 0.3% by mass or less, more preferably 0.25% by mass or less, even more preferably 0.2% by mass or less, and even more preferably 0.15% by mass or less. Furthermore, the content of component (B) in the oral composition of the present invention is preferably 0.005 to 0.3% by mass, more preferably 0.005 to 0.25% by mass, even more preferably 0.03 to 0.2% by mass, and even more preferably 0.05 to 0.15% by mass. The content of component (B) can be measured by a commonly known analytical method appropriate to the conditions of the measurement sample, for example, liquid chromatography. Specific examples include the methods described in the Examples below. During measurement, the sample may be freeze-dried to fit the detection range of the instrument, or impurities may be removed from the sample to fit the resolution of the instrument, or other appropriate treatments may be performed as needed.
[0014] In order to suppress astringency, the oral composition of the present invention is characterized in that the mass ratio of component (A) to component (B) [(B) / (A)] is 1×10 -4 It is preferable that the ratio is 3×10 or more. -4 More preferably, 5 × 10 -4 More preferably, 500×10 -4 The following is preferred: 300 x 10 -4 Less than 100 x 10 is more preferable. -4 The mass ratio [(B) / (A)] in the oral composition of the present invention is preferably 1×10 -4 Above 500 x 10 -4 or less, and more preferably 3×10 -4 300 x 10 or more -4 or less, and more preferably 5×10-4 Above 100 x 10 -4 The following is the result.
[0015] The oral composition of the present invention contains 4-vinylguaiacol as component (C). 4-vinylguaiacol is known not only as a substance that inhibits the crisp aftertaste of roasted coffee beverages, but also as an off-flavor substance in sake, such as a smoky, chemical, or spicy odor. However, the present invention has surprisingly found that by incorporating component (C) in a mass ratio relative to component (B) within a specific range, it is possible to suppress the astringency that specifically occurs when a trace amount of caffeine is contained in a high concentration of chlorogenic acids. Component (C) may be derived from the raw materials or may be newly added.
[0016] The oral composition of the present invention has a mass ratio of component (B) to component (C) [(C) / (B)] of 3×10 -4 Above 1100 x 10 -4 From the viewpoint of suppressing astringency, -4 More than 6 × 10 is preferable. -4 More preferably, 8×10 -4 The above is more preferable, and from the viewpoint of suppressing the chemical odor derived from 4-vinylguaiacol, 400×10 -4 The following is preferred: 250 x 10 -4 More preferably, 150 x 10 -4 The mass ratio [(C) / (B)] in the oral composition of the present invention is preferably 4×10 -4 Above 400 x 10 -4 or less, and more preferably 6×10 -4 Above 250 x 10 -4 is preferably 8×10 or less. -4 Above 150 x 10 -4 The mass ratio [(C) / (B)] is calculated using the same units for the contents of component (B) and component (C).
[0017] In addition, the oral composition of the present invention has a mass ratio of component (A) to component (C) [(C) / (A)] of 1×10 -6 More than 3 × 10-6 More preferably, 5 × 10 -6 More preferably, 40×10 -6 The above is even more preferable, and from the viewpoint of suppressing the chemical odor derived from 4-vinylguaiacol, 300×10 -6 The following is preferred: 180 x 10 -6 More preferably, 120 x 10 -6 More preferably, 80×10 -6 The mass ratio [(C) / (A)] in the oral composition of the present invention is preferably 1×10 -6 300 x 10 or more -6 or less, and more preferably 3×10 -6 Above 180 x 10 -6 or less, and more preferably 5×10 -6 Above 120 x 10 -6 and even more preferably 40×10 -6 Above 80 x 10 -6 The mass ratio [(C) / (A)] is calculated using the same units for the contents of component (A) and component (C).
[0018] The content of component (C) in the oral composition of the present invention is preferably 0.1 ppm by mass or more, more preferably 0.3 ppm by mass or more, even more preferably 0.7 ppm by mass or more, and even more preferably 6 ppm by mass or more, from the viewpoint of suppressing astringency. Furthermore, from the viewpoint of suppressing the chemical odor derived from 4-vinylguaiacol, the content is preferably 60 ppm by mass or less, more preferably 25 ppm by mass or less, even more preferably 20 ppm by mass or less, and even more preferably 15 ppm by mass or less. The content of component (C) in the oral composition of the present invention is preferably 0.1 to 60 ppm by mass, more preferably 0.3 to 25 ppm by mass, even more preferably 0.7 to 20 ppm by mass, and even more preferably 6 to 15 ppm by mass. The content of component (C) can be measured by a commonly known analytical method appropriate to the conditions of the measurement sample, for example, by GC / MS. Specific examples include the methods described in the Examples below. During measurement, the sample may be freeze-dried to fit the detection range of the instrument, or impurities may be removed from the sample to fit the resolution of the instrument, or other appropriate treatments may be performed as needed.
[0019] Furthermore, the oral composition of the present invention may contain a lactone as component (D). Lactones are known as compounds with a unique odor. The present inventors have discovered that, although the inclusion of lactone alone is unable to suppress the astringency that specifically occurs when a trace amount of caffeine is present in a high concentration of chlorogenic acids, the inclusion of lactone in combination with 4-vinylguaiacol enhances the astringency suppression effect. Component (D) may be derived from the raw materials or may be newly added.
[0020] Component (D) is not particularly limited as long as it is a lactone, but from the viewpoint of suppressing astringency, it is preferably one or more selected from γ-butyrolactone, γ-decalactone, and δ-decanolactone, and more preferably γ-butyrolactone.
[0021] In the oral composition of the present invention, the mass ratio of component (B) to component (D) [(D) / (B)] is 3×10 -4 More than 8 × 10 is preferable. -4More preferably, 20 × 10 -4 The above is more preferable, and from the viewpoint of suppressing unpleasant odors derived from lactone, 1200×10 -4 Preferably, 500 x 10 -4 More preferably, 300 x 10 -4 The mass ratio [(D) / (B)] in the oral composition of the present invention is preferably 3×10 -4 Above 1200 x 10 -4 or less, more preferably 8×10 -4 Above 500 x 10 -4 or less, and more preferably 20×10 -4 300 x 10 or more -4 The mass ratio [(D) / (B)] is calculated using the same units for the contents of component (B) and component (D).
[0022] Furthermore, in the oral composition of the present invention, the mass ratio of component (C) to component (D) [(D) / (C)] is preferably 0.1 or more, more preferably 0.5 or more, and even more preferably 1.5 or more from the viewpoint of suppressing astringency, and is preferably 50 or less, more preferably 25 or less, and even more preferably 15 or less from the viewpoint of suppressing unpleasant odors derived from lactones. The mass ratio [(D) / (C)] in the oral composition of the present invention is preferably 0.1 to 50, more preferably 0.5 to 25, and even more preferably 1.5 to 15.
[0023] The content of component (D) in the oral composition of the present invention is preferably 0.1 ppm by mass or more, more preferably 0.5 ppm by mass or more, and even more preferably 1.5 ppm by mass or more, from the viewpoint of suppressing astringency. Furthermore, from the viewpoint of suppressing off-flavors derived from lactones, it is preferably 90 ppm by mass or less, more preferably 60 ppm by mass or less, and even more preferably 40 ppm by mass or less. The content of component (D) in the oral composition of the present invention is preferably 0.1 to 90 ppm by mass, more preferably 0.5 to 60 ppm by mass, and even more preferably 1.5 to 40 ppm by mass. The content of component (D) can be measured by any commonly known analytical method suited to the conditions of the sample to be measured, for example, GC / MS. Specific examples include the methods described in the Examples below. During measurement, the sample may be subjected to appropriate treatment as needed, such as freeze-drying to fit the detection range of the instrument or removing impurities from the sample to match the resolution of the instrument.
[0024] The oral composition of the present invention may optionally contain one or more additives such as sweeteners, acidulants, amino acids, proteins, vitamins, minerals, flavorings, fruit juices, plant extracts, esters, colorings, emulsifiers, milk components, cocoa powder, seasonings, vegetable oils and fats, antioxidants, preservatives, pH adjusters, gelling agents, carriers, etc. The content of the additives can be appropriately set within a range that does not impair the object of the present invention.
[0025] As used herein, the term "oral composition" refers to a composition that is unlikely to be harmful to human health and is primarily taken orally in normal social life, and is not limited to administrative classifications such as food, medicine, quasi-drug, etc. Therefore, the oral composition of the present invention broadly encompasses foods and beverages that constitute orally ingested general foods, health foods (functional foods and beverages), health functional foods (foods for specified health uses, foods with nutrient functions, foods with functional claims), quasi-drugs, medicines, etc.
[0026] The oral composition of the present invention may be in a liquid or solid form at room temperature (20°C ± 15°C), and may take any appropriate form.
[0027] The oral composition of the present invention is preferably used for oral compositions other than coffee beverages. Coffee beverages typically contain 0.00006% by mass or more of furfuryl mercaptan (hereinafter referred to as "component (E)"), making them clearly distinguishable from the oral composition of the present invention. That is, the oral composition of the present invention contains less than 0.00006% by mass of component (E), preferably less than 0.00003% by mass, more preferably less than 0.00001% by mass, and even more preferably substantially free of component (E). Herein, "substantially free of component (E)" encompasses not only the complete absence of component (E) in the oral composition of the present invention, but also a concentration below the detection limit. The content of component (E) can be measured by any commonly known analytical method appropriate to the conditions of the sample, such as GC / MS. Specifically, the method described in the Examples below can be used. During measurement, the sample may be freeze-dried to fit the detection range of the instrument, or impurities may be removed from the sample to fit the resolution of the instrument, or other appropriate treatments may be performed as needed.
[0028] When a natural product is used as component (A) in the oral composition of the present invention, lightly roasted coffee beans or green coffee beans are preferred from the viewpoint of chlorogenic acid content. Herein, "lightly roasted coffee beans" refers to roasted coffee beans with an L value of 30 or more and 60 or less. From the viewpoint of the physiological effect of component (A), the L value of lightly roasted coffee beans is preferably 32 or more, more preferably 34 or more, even more preferably 36 or more, even more preferably 38 or more, and even more preferably 40 or more. Note that, in this specification, "L value" refers to the brightness of roasted coffee beans measured with a colorimeter, with black being an L value of 0 and white being an L value of 100. The type and origin of the coffee beans are not particularly limited. Furthermore, one or more types of coffee beans with different types and origins may be used.
[0029] On the other hand, coffee beverages typically use roasted coffee beans as an ingredient, including roasted coffee beans with an L value of less than 30. Therefore, the concept of the oral composition of the present invention does not encompass oral compositions (e.g., coffee beverages) that use roasted coffee beans as an ingredient, including roasted coffee beans with an L value of preferably less than 30, more preferably less than 32, even more preferably less than 34, even more preferably less than 36, even more preferably less than 38, and especially preferably less than 40. The coffee content in a coffee beverage is calculated by extracting or eluting coffee from at least 1 g of roasted coffee beans per 100 g of content, calculated as green coffee beans. Here, "green coffee equivalent" means that 1 g of roasted coffee beans is equivalent to 1.3 g of green coffee beans (see page 421 of Revised New Edition of Soft Drinks, edited by the Japan Soft Drink Association, published by Korin, published December 25, 1989). Furthermore, the type of coffee beverage is not particularly limited, but examples include coffee beverages, etc., as defined in Article 2 of the "Fair Competition Code on the Labeling of Coffee Beverages, etc." revised and enforced on August 19, 2019, namely, "coffee," "coffee beverage," "coffee-containing soft drink," and "coffee-containing carbonated beverage."
[0030] Components (B) to (D) may be chemically synthesized products (e.g., reagents) or products derived from natural products. Examples of products derived from natural products include plants, and they may be extracts. Examples of plants containing component (B) include, but are not limited to, coffee beans and tea leaves. Examples of plants containing component (C) include, but are not limited to, coffee beans, rice bran, and wheat bran. Examples of plants containing component (D) include, but are not limited to, coffee beans, grapes, and apricot pulp. One or more types of plants can be used. The extraction method and conditions for the plant extract are not particularly limited, and known methods can be used. The plant extract may be a concentrate or a dried product.
[0031] Suitable embodiments of the oral composition of the present invention include, for example, a solid oral composition and a liquid oral composition. Each of these compositions will be described below in accordance with a preferred embodiment.
[0032] The solid oral composition of the present invention may be in any form, as long as it is solid at room temperature (20°C ± 15°C), including, for example, powder, granules, tablets, rods, plates, blocks, and the like. The solid content of the solid oral composition of the present invention is typically 90% by mass or more, preferably 93% by mass or more, more preferably 95% by mass or more, and even more preferably 97% by mass or more. The upper limit of the solid content is not particularly limited, and may be 100% by mass. Herein, the term "solid content" refers to the mass of the residue remaining after drying 1 g of a sample in an electric thermostatic dryer at 105°C for 3 hours and removing volatile substances.
[0033] Examples of the solid oral composition of the present invention include foods, pharmaceuticals, and quasi-drugs. Among these, solid foods are preferred, and powdered foods are more preferred, in that the effects of the present invention can be easily enjoyed. When the solid oral composition of the present invention is a solid food, examples include confectioneries such as candy, candy, gum, chocolate, and cookies and bread; and health, beauty, and nutritional supplements such as supplements. When the solid oral composition of the present invention is a pharmaceutical or quasi-drug, its dosage form may be, for example, granules, powders, tablets, pills, chewable tablets, lozenges, etc. When made into tablets, they may also be divided tablets with a score line. Among these, supplements, powders, tablets, and granules are preferred as solid oral compositions.
[0034] The solid oral composition of the present invention may contain an acceptable carrier as needed to make it into a solid form. Examples of the carrier include excipients (e.g., starches such as waxy cornstarch, sweet potato starch, potato starch, etc.; sugar alcohols such as xylitol, sorbitol, maltitol, lactitol, reduced palatinose, trehalose, palatinose, etc.; lactose; oligosaccharides; crystalline cellulose; light anhydrous silicic acid; calcium hydrogen phosphate, etc.), binders (e.g., gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol, pullulan, hydrogenated oil, etc.), disintegrants (e.g., carmellose, carmellose calcium, croscarmellose sodium, crospovidone), lubricants (e.g., calcium stearate, magnesium stearate, sucrose fatty acid esters, sodium stearyl fumarate, talc, silicon dioxide, etc.), flavoring agents (e.g., stevia, etc.), bulking agents, surfactants, dispersants, buffers, antioxidants, preservatives, quality stabilizers, diluents, etc.
[0035] The solid oral composition of the present invention may also be made into an instant beverage composition. As used herein, the term "instant beverage composition" refers to a composition that is diluted with a liquid according to a prescribed method of use and orally ingested as a reconstituted beverage. The liquid is not particularly limited as long as it can be reconstituted into a beverage, and examples include water, carbonated water, milk, soy milk, etc., and the temperature of the liquid does not matter. The dilution ratio may be determined according to the prescribed method of use, but is typically 30 to 800 times by weight, preferably 80 to 600 times by weight.
[0036] The solid oral composition of the present invention can be produced by conventional methods, and any suitable method can be employed. For example, it can be produced by mixing components (A) to (C) and, if necessary, other components, so that the respective contents of components (A) and (B) and the mass ratio of components (B) to (C) [(C) / (B)] fall within the above-mentioned ranges. The order in which components (A) to (C) and other components are mixed is not particularly limited, and they can be mixed in any order. Any suitable mixing method, such as stirring or shaking, can be used, but a mixing device can also be used. The mixing method of the mixing device can be either a rotating container type or a fixed container type. Examples of rotating container types that can be used include horizontal cylindrical, V-type, double-cone, and cubic types. Examples of fixed container types that can be used include ribbon, screw, conical screw, paddle, fluidized bed, and Phillips blenders.
[0037] The solid oral composition of the present invention may be granulated by a known granulation method. Examples of the granulation method include spray granulation, fluidized bed granulation, compression granulation, tumbling granulation, stirring granulation, extrusion granulation, and powder coating granulation. Granulation conditions can be appropriately selected depending on the granulation method. When forming tablets, either wet tableting or dry tableting may be used, and a known compression molding machine can be used.
[0038] The solid oral composition of the present invention can be filled into a package. Examples of the package include bottles, cans, jars, box-shaped containers, stick-type packages, and pillow-type packages. A commercially available filling machine may be used to fill the solid oral composition of the present invention into a package. The solid oral composition of the present invention can be packaged, for example, in single-serving portions. In the case of an instant beverage composition, it can be, for example, a bottle or the like in which a cupful is measured out with a spoon or the like, a cup-type containing a single serving, or a stick-type packaged in individual cupfuls. The container and packaging may be filled with nitrogen gas, and packaging with low oxygen permeability is preferred in terms of maintaining quality.
[0039] The form of the liquid oral composition of the present invention is not particularly limited as long as it has fluidity at room temperature (20°C ± 15°C), and examples thereof include liquid, concentrated liquid, gel, and jelly forms.
[0040] Examples of product forms of the liquid oral composition of the present invention include RTD (ready-to-drink) beverage compositions; dairy products such as yogurt, processed milk, and fermented milk; oils and fats and processed oil foods such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressings; seasonings such as sauces and dressings; and health, beauty, and nutritional supplements such as energy drinks. Here, in this specification, "RTD beverage composition" refers to a beverage that can be consumed as is without dilution.
[0041] Among these, RTD beverage compositions are preferred as liquid oral compositions. Examples of the form of RTD beverage compositions include liquid, concentrated liquid, gel, and jelly. When the form is concentrated liquid, gel, or jelly, the beverage composition may be drawn through a spout or straw attached to the container, and the solids concentration is not particularly limited.
[0042] From the viewpoint of flavor, the pH (20°C) of the RTD beverage composition is preferably 3 or higher, more preferably 3.5 or higher, even more preferably 4 or higher, and preferably 7 or lower, more preferably 6.5 or lower, even more preferably 6 or lower. The pH is measured with a pH meter at a temperature adjusted to 20°C.
[0043] The RTD beverage composition may be either a non-alcoholic beverage or an alcoholic beverage. Herein, "non-alcoholic beverage" refers to a beverage with an alcohol concentration of less than 1 v / v%, and also includes beverages containing no alcohol at all and beverages with an alcohol concentration of 0.00 v / v%. In this specification, "alcohol" refers to ethanol unless otherwise specified. Examples of non-alcoholic beverages include tea beverages, carbonated beverages, fruit juice beverages, vegetable beverages, dairy beverages, sports drinks, isotonic beverages, enhanced water, bottled water, near-water, nutritional drinks, beauty drinks, etc. Examples of alcoholic beverages include beer, wine, sake, plum wine, happoshu, whiskey, brandy, shochu, rum, gin, liqueurs, etc.
[0044] The RTD beverage composition may be packaged in a container. The container is not particularly limited as long as it is a common packaging container, and examples thereof include molded containers primarily made of polyethylene terephthalate (so-called PET bottles), metal cans, paper containers combined with metal foil or plastic film, bottles, and the like.
[0045] When the RTD beverage composition is a packaged beverage composition, it may be heat-sterilized. The heat-sterilization method is not particularly limited as long as it complies with the conditions stipulated in applicable laws and regulations (such as the Food Sanitation Act in Japan).
[0046] The liquid oral composition of the present invention can be produced by conventional methods, and any suitable method can be used. For example, it can be produced by mixing components (A) to (C) and, if necessary, other components with a liquid so that the respective contents of components (A) and (B) and the mass ratio of components (B) to (C) [(C) / (B)] are within the above-mentioned ranges. The order in which components (A) to (C) and other components are mixed is not particularly limited, and they can be mixed in any order. Examples of liquids include water, carbonated water, milk, and soy milk, and the temperature of the liquid is not important.
[0047] [Astringency suppressant and astringency suppression method] The astringency suppressant of the present invention is an astringency suppressant for oral use containing (C) 4-vinylguaiacol as an active ingredient, 5 to 20% by mass of (A) chlorogenic acids, and 0.001% by mass or more but less than 0.4% by mass of (B) caffeine, wherein the mass ratio of (C) 4-vinylguaiacol to (B) caffeine [(C) / (B)] is 3 × 10 -4 Above 1100 x 10 -4 The astringency suppression method of the present invention is a method for suppressing the astringency of an oral product containing 5 to 20% by mass of (A) chlorogenic acids and 0.001% by mass or more but less than 0.4% by mass of (B) caffeine, in which (C) 4-vinylguaiacol is present in an amount of 3×10 to 50% by mass of caffeine (B) [(C) / (B)]. -4 Above 1100 x 10 -4 They should coexist in the following proportions.
[0048] The oral product is not particularly limited as long as it can be orally ingested, and may be liquid or solid. Examples include foods and beverages, pharmaceuticals, or quasi-drugs containing component (A) and component (B). Among these, foods and beverages are preferred. Examples of foods and beverages include beverages or instant drinks containing component (A) and component (B), and foods containing component (A) and (B). The foods and beverages can be produced according to conventional methods depending on the type of food and beverage. The contents of component (A) and component (B) in the oral product and the mass ratios between the components are as described above.
[0049] In addition, in order to enhance the suppression of astringency in the oral product, (D) lactone may be present together with (C) 4-vinylguaiacol. Note that the specific embodiment of component (D), the content of component (D) in the oral product, and the mass ratio between the components are as described above.
[0050] The dosage form of the pharmaceuticals and quasi-drugs is not particularly limited, and examples thereof include oral administration formulations, and known dosage forms such as liquids and syrups can be used. Furthermore, known additives can be blended when the formulations are prepared. Pharmaceuticals and quasi-drugs can be manufactured according to conventional methods.
[0051] In relation to the above-described embodiment, the present invention further discloses the following aspects.
[0052] <1> A composition comprising the following components (A), (B), and (C): (A) 5 to 20% by mass of chlorogenic acids, (B) 0.001% by mass or more and less than 0.4% by mass of caffeine, and (C) 4-vinylguaiacol, wherein the mass ratio of the component (B) to the component (C) [(C) / (B)] is 3×10 -4 Above 1100 x 10 -4 An oral composition comprising:
[0053] <2> The oral composition according to the above <1>, wherein the content of component (A) is preferably 6% by mass or more, more preferably 6.5% by mass or more, even more preferably 7% by mass or more, and preferably 18% by mass or less, more preferably 17% by mass or less, and even more preferably 16% by mass or less. <3> The oral composition according to the above <1>, wherein the content of component (A) is preferably 6 to 18% by mass, more preferably 6.5 to 17% by mass, and even more preferably 7 to 16% by mass.
[0054] <4> The oral composition according to any one of the above <1> to <3>, wherein the content of component (B) is preferably 0.005% by mass or more, more preferably 0.03% by mass or more, even more preferably 0.05% by mass or more, and preferably 0.3% by mass or less, more preferably 0.25% by mass or less, even more preferably 0.2% by mass or less, and still more preferably 0.15% by mass or less. <5> The oral composition according to any one of the above <1> to <3>, wherein the content of component (B) is preferably 0.005 to 0.3% by mass, more preferably 0.005 to 0.25% by mass, even more preferably 0.03 to 0.2% by mass, and still more preferably 0.05 to 0.15% by mass.
[0055] <6> The mass ratio of the component (A) to the component (B) [(B) / (A)] is preferably 1×10 -4 More preferably, 3×10 -4 or more, and more preferably 5×10 -4 or more, and preferably 500×10 -4 More preferably, it is 300×10 or less. -4 or less, and more preferably 100×10 -4 <7> The composition for oral administration according to any one of the above items <1> to <5>, wherein the mass ratio of component (A) to component (B) [(B) / (A)] is preferably 1 x 10 -4 Above 500 x 10 -4 or less, and more preferably 3×10 -4 300 x 10 or more -4 or less, and more preferably 5×10 -4 Above 100 x 10 -4 The oral composition according to any one of <1> to <5>, which is:
[0056] <8> The oral composition according to any one of the above <1> to <7>, wherein the content of component (C) is preferably 0.1 ppm by mass or more, more preferably 0.3 ppm by mass or more, even more preferably 0.7 ppm by mass or more, still more preferably 6 ppm by mass or more, and preferably 60 ppm by mass or less, more preferably 25 ppm by mass or less, even more preferably 20 ppm by mass or less, and still more preferably 15 ppm by mass or less. <9> The oral composition according to any one of the above <1> to <7>, wherein the content of component (C) is preferably 0.1 to 60 ppm by mass, more preferably 0.3 to 25 ppm by mass, even more preferably 0.7 to 20 ppm by mass, and still more preferably 6 to 15 ppm by mass.
[0057] <10> The mass ratio of the component (B) to the component (C) [(C) / (B)] is preferably 4×10 -4 More preferably, 6×10 -4 or more, and more preferably 8×10 -4 or more, and preferably 400×10-4 or less, more preferably 250 × 10 -4 or less, and more preferably 150×10 -4 <11> The composition for oral administration according to any one of the above items <1> to <9>, wherein the mass ratio of component (B) to component (C) [(C) / (B)] is preferably 4 x 10 -4 Above 400 x 10 -4 or less, and more preferably 6×10 -4 Above 250 x 10 -4 is preferably 8×10 or less. -4 Above 150 x 10 -4 The oral composition according to any one of <1> to <9>, which is:
[0058] <12> The mass ratio of the component (A) to the component (C) [(C) / (A)] is preferably 1×10 -6 More preferably, 3×10 -6 or more, and more preferably 5×10 -6 More preferably, it is 40×10 -6 or more, and preferably 300×10 -6 or less, and more preferably 180×10 -6 or less, and more preferably 120×10 -6 or less, and even more preferably 80×10 -6 <13> The composition for oral administration according to any one of the above items <1> to <11>, wherein the mass ratio of component (A) to component (C) [(C) / (A)] is preferably 1 x 10 -6 300 x 10 or more -6 or less, and more preferably 3×10 -6 Above 180 x 10 -6 or less, and more preferably 5×10 -6 Above 120 x 10 -6 and even more preferably 40×10 -6 Above 80 x 10 -6 The oral composition according to any one of <1> to <11>, which is:
[0059] <14> The composition for oral administration according to any one of the above items <1> to <13>, preferably further comprising a lactone as component (D). <15> The composition for oral administration according to the above item <14>, wherein component (D) is preferably one or more selected from γ-butyrolactone, γ-decalactone, and δ-decanolactone, more preferably γ-butyrolactone.
[0060] <16> The oral composition according to the above <14> or <15>, wherein the content of component (D) is preferably 0.1 ppm by mass or more, more preferably 0.5 ppm by mass or more, even more preferably 1.5 ppm by mass or more, and preferably 90 ppm by mass or less, more preferably 60 ppm by mass or less, and even more preferably 40 ppm by mass or less. <17> The oral composition according to the above <14> or <15>, wherein the content of component (D) is preferably 0.1 to 90 ppm by mass, more preferably 0.5 to 60 ppm by mass, and even more preferably 1.5 to 40 ppm by mass.
[0061] <18> The mass ratio of the component (B) to the component (D) [(D) / (B)] is preferably 3×10 -4 More preferably, 8×10 -4 More preferably, it is 20×10 -4 or more, and preferably 1200 x 10 -4 or less, more preferably 500×10 -4 or less, and more preferably 300×10 -4 <19> The composition for oral administration according to any one of the above items <14> to <17>, wherein the mass ratio of component (B) to component (D) [(D) / (B)] is preferably 3 x 10 -4 Above 1200 x 10 -4 or less, more preferably 8×10 -4 Above 500 x 10 -4 or less, and more preferably 20×10 -4 300 x 10 or more -4 The composition for oral administration according to any one of the above items <14> to <17>, which is:
[0062] <20> The oral composition according to any one of the above <14> to <19>, wherein the mass ratio of component (C) to component (D) [(D) / (C)] is preferably 0.1 or more, more preferably 0.5 or more, even more preferably 1.5 or more, and preferably 50 or less, more preferably 25 or less, and even more preferably 15 or less. <21> The oral composition according to any one of the above <14> to <19>, wherein the mass ratio of component (C) to component (D) [(D) / (C)] is preferably 0.1 to 50, more preferably 0.5 to 25, and even more preferably 1.5 to 15.
[0063] <22> The composition for oral administration according to any one of the above <1> to <21>, preferably excluding a coffee beverage. <23> The composition for oral administration according to any one of the above <1> to <22>, preferably containing furfuryl mercaptan as component (E), in which the content of component (E) is preferably less than 0.00006% by mass, more preferably less than 0.00003% by mass, even more preferably less than 0.00001% by mass, and still more preferably substantially free of component (E).
[0064] <24> The oral composition according to any one of the above <1> to <23>, wherein component (A) is preferably derived from one or more selected from lightly roasted coffee beans and green coffee beans. <25> The oral composition according to the above <24>, wherein the L value of the lightly roasted coffee beans is preferably 30 or more, more preferably 32 or more, even more preferably 34 or more, even more preferably 36 or more, even more preferably 38 or more, still more preferably 40 or more, and preferably 60 or less. <26> The oral composition according to the above <24>, wherein the L value of the lightly roasted coffee beans is preferably 30 to 60, more preferably 32 to 60, even more preferably 34 to 60, even more preferably 36 to 60, even more preferably 38 to 60, and still more preferably 40 to 60.
[0065] <27> The composition for oral administration according to any one of the above items <1> to <26>, excluding an oral composition using, as a raw material, roasted coffee beans, the L value of which is preferably less than 30, more preferably less than 32, even more preferably less than 34, still more preferably less than 36, even more preferably less than 38, and still more preferably less than 40.
[0066] <28> The oral composition according to any one of the above <1> to <27>, which is preferably a solid oral composition. <29> The oral composition according to the above <28>, which is preferably solid at room temperature (20°C±15°C). <30> The oral composition according to the above <28> or <29>, which is preferably in the form of powder, granules, tablets, rods, plates or blocks. <31> The oral composition according to any one of the above <28> to <30>, which has a solid content of preferably 90% by mass or more, more preferably 93% by mass or more, even more preferably 95% by mass or more, and still more preferably 97% by mass or more. <32> The oral composition according to any one of the above <28> to <31>, which is preferably a food, a drug or a quasi-drug, and even more preferably a solid food or a powdered food. <33> The oral composition according to any one of the above <28> to <32>, which is preferably a confectionery, a supplement, a health food, a beauty food, or a nutritional supplement, more preferably a supplement. <34> The oral composition according to any one of the above <28> to <32>, which is preferably in the form of granules, powders, tablets, pills, chewable tablets, or lozenges, more preferably in the form of powders, tablets, or granules. <35> The oral composition according to any one of the above <28> to <34>, which preferably contains one or more carriers selected from excipients, binders, disintegrants, lubricants, fillers, surfactants, dispersants, buffers, antioxidants, preservatives, stabilizers, and diluents. <36> The oral composition according to any one of the above <28> to <35>, which is preferably an instant beverage composition.
[0067] 1. Analysis of chlorogenic acids and caffeine HPLC was used as the analytical instrument. The model numbers of the components of the device are as follows: UV-VIS detector: SPD-20A (Shimadzu Corporation) Column oven: CTO-20AC (Shimadzu Corporation) Pump: LC-20AD (Shimadzu Corporation) Autosampler: SIL-20AC (Shimadzu Corporation) Column: Cadenza CD-C18, inner diameter 4.6 mm x length 150 mm, particle size 3 μm (Intact Corporation)
[0068] The analytical conditions were as follows: Sample injection volume: 10 μL Flow rate: 1.0 mL / min UV-VIS detector wavelength setting: 325 nm (chlorogenic acids), 270 nm (caffeine) Column oven temperature setting: 35°C Eluent A: 50 mM acetic acid, 0.1 mM 1-hydroxyethane-1,1-diphosphonic acid, 10 mM sodium acetate, 5 (V / V) % acetonitrile solution Eluent B: acetonitrile
[0069] Concentration gradient conditions (volume %) Time Eluent A Eluent B 0.0 min 100% 0% 10.0 min 100% 0% 15.0 min 95% 5% 20.0 min 95% 5% 22.0 min 92% 8% 50.0 min 92% 8% 52.0 min 10% 90% 60.0 min 10% 90% 60.1 min 100% 0% 70.0 min 100% 0%
[0070] 3-Caffeoylquinic acid: 5.3 min 5-Caffeoylquinic acid: 8.8 min 4-Caffeoylquinic acid: 11.6 min 3-Ferulaconic acid: 13.0 min 5-Ferulaconic acid: 19.9 min 4-Ferulaconic acid: 21.0 min 3,4-Dicaffeoylquinic acid: 36.6 min 3,5-Dicaffeoylquinic acid: 37.4 min 4,5-Dicaffeoylquinic acid: 44.2 min From the area% determined here, the chlorogenic acid content (mass%) was determined using 5-caffeoylquinic acid (Tokyo Chemical Industry Co., Ltd.) as the standard substance.
[0071] Caffeine: 19.1 min From the area % calculated here, the caffeine content (mass %) was calculated using caffeine (Fujifilm Wako Pure Chemical Industries, Ltd.) as a standard substance.
[0072] 2. Analysis of 4-vinylguaiacol and lactones Samples were placed in vials, and aroma components in the headspace were adsorbed using an SPME fiber and subjected to GC / MS measurement.
[0073] The analytical conditions were as follows: HS-GC / MS conditions: Measurement equipment: HP6890 (Agilent) Column: VF-WAX, inner diameter 0.25 mm, length 60 m, film thickness 0.25 μm (GL Sciences) Column temperature: 35°C (4 min) → 3°C / min → 130°C → 5°C / min → 240°C (15 min) Column pressure: constant flow mode (31 kPa) Column flow rate: 1.5 mL / min (He) Injection port temperature: 240°C Injection method: splitless Detector temperature: 200°C Carrier gas: helium Scan mode: m / z 30-500
[0074] The purchased reagent was dissolved in ethanol and serially diluted to prepare a standard sample. A predetermined concentration of the standard was added to the sample, and the sample was adsorbed onto an SPME fiber in the same manner as the sample alone, followed by GC / MS measurement. The following m / z peak areas were used to quantify 4-vinylguaiacol, γ-butyrolactone, γ-decalactone, and δ-decanolactone.
[0075] γ-butyrolactone: 42 γ-decalactone: 85 δ-decanolactone: 99 4-vinylguaiacol: 150
[0076] Production Example 1: Production of Green Coffee Bean Extract Green coffee bean extract powder (90 g solids) was dissolved in 360 g of ethanol solution with an ethanol concentration of 60% by mass, mixed with 45 g of acid clay (Mizuka Ace #600, manufactured by Mizusawa Chemical Industries, Ltd.), and filtered through filter paper pre-coated with diatomaceous earth. The filtrate was passed through a column packed with 34 mL of coconut shell activated carbon and a column packed with 31 mL of H-type cation exchange resin to obtain a column-treated solution. The column-treated solution was concentrated to obtain a chlorogenic acid preparation. The chlorogenic acid content of the obtained chlorogenic acid preparation was 38% by mass, and the caffeine concentration was 0.0% by mass.
[0077] Examples 1 to 13, Comparative Examples 1 and 2, and Reference Example 1 Solid oral compositions were prepared by uniformly mixing the components shown in Table 1, and the resulting solid oral compositions were analyzed and subjected to the following sensory evaluation. The results are shown in Table 1.
[0078] Sensory evaluation: A sensory test was conducted by three expert panelists on the "astringency" of the solid oral compositions obtained in each Example, Comparative Example, and Reference Example, after agreeing on the following evaluation criteria. The final evaluation score was then determined by discussion based on the scores determined by each expert panelist.
[0079] Evaluation criteria for astringency The astringency of the solid oral composition of Comparative Example 1 was scored as "1", and the astringency of the solid oral composition of Reference Example 1 was scored as "5", and the evaluation was carried out according to the following criteria: Score 5: No astringency felt 4: Almost no astringency felt 3: Slight astringency felt 2: Astringency felt 1: Strong astringency felt
[0080]
[0081] Examples 14 to 20, Comparative Example 3 and Reference Example 2 Solid oral compositions were prepared by uniformly mixing the components shown in Table 2, and the resulting solid oral compositions were analyzed and subjected to the following sensory evaluation. The results are shown in Table 2.
[0082] Sensory evaluation: A sensory test was conducted by three expert panelists on the "astringency" of the solid oral compositions obtained in each Example, Comparative Example, and Reference Example, after agreeing on the following evaluation criteria. The final evaluation score was then determined by discussion based on the scores determined by each expert panelist.
[0083] Evaluation criteria for astringency The astringency of the solid oral composition of Comparative Example 3 was scored as "1", and the astringency of the solid oral composition of Reference Example 2 was scored as "5", and the evaluation was carried out according to the following criteria: Score 5: No astringency felt 4: Almost no astringency felt 3: Slight astringency felt 2: Astringency felt 1: Strong astringency felt
[0084]
[0085] Examples 21 to 23, Comparative Example 4 and Reference Example 3 Solid oral compositions were prepared by uniformly mixing the components shown in Table 3, and the resulting solid oral compositions were analyzed and subjected to the following sensory evaluation. The results are shown in Table 3.
[0086] Sensory evaluation: A sensory test was conducted by three expert panelists on the "astringency" of the solid oral compositions obtained in each Example, Comparative Example, and Reference Example, after agreeing on the following evaluation criteria. The final evaluation score was then determined by discussion based on the scores determined by each expert panelist.
[0087] Evaluation criteria for astringency The astringency of the solid oral composition of Comparative Example 4 was scored as "1", and the astringency of the solid oral composition of Reference Example 3 was scored as "5", and the evaluation was carried out according to the following criteria: Score 5: No astringency felt 4: Almost no astringency felt 3: Slight astringency felt 2: Astringency felt 1: Strong astringency felt
[0088]
[0089] Examples 24 to 26, Comparative Example 5 and Reference Example 4 Solid oral compositions were prepared by uniformly mixing the components shown in Table 4, and the resulting solid oral compositions were analyzed and subjected to the following sensory evaluation. The results are shown in Table 4.
[0090] Sensory evaluation: A sensory test was conducted by three expert panelists on the "astringency" of the solid oral compositions obtained in each Example, Comparative Example, and Reference Example, after agreeing on the following evaluation criteria. The final evaluation score was then determined by discussion based on the scores determined by each expert panelist.
[0091] Evaluation criteria for astringency The astringency of the solid oral composition of Comparative Example 5 was scored as "1", and the astringency of the solid oral composition of Reference Example 4 was scored as "5", and the evaluation was carried out according to the following criteria: Score 5: No astringency felt 4: Almost no astringency felt 3: Slight astringency felt 2: Astringency felt 1: Strong astringency felt
[0092]
[0093] It is clear from Tables 1 to 4 that the astringency that occurs when a trace amount of caffeine is added to a high concentration of chlorogenic acids can be suppressed by adding 4-vinylguaiacol to the caffeine in a certain ratio. Furthermore, it is clear that this astringency suppression effect is not achieved by lactone alone, but is enhanced by adding lactone together with 4-vinylguaiacol.
Claims
1. A composition comprising the following components (A), (B), and (C): (A) 5 to 20% by mass of chlorogenic acids, (B) 0.001% by mass or more but less than 0.4% by mass of caffeine, and (C) 4-vinylguaiacol, wherein the mass ratio of component (B) to component (C) [(C) / (B)] is 3 x 10 -4 Above 1100 x 10 -4 An oral composition comprising:
2. The mass ratio of component (A) to component (C) [(C) / (A)] is 1 x 10 -6 300 x 10 or more -6 2. The oral composition of claim 1, wherein:
3. The mass ratio of component (A) to component (B) [(B) / (A)] is 1 x 10 -4 Above 500 x 10 -4 3. The oral composition according to claim 1 or 2, wherein:
4. The oral composition according to any one of claims 1 to 3, wherein the content of component (C) is 0.1 to 60 ppm by mass.
5. The oral composition according to any one of claims 1 to 4, further comprising a lactone as component (D).
6. The oral composition of claim 5, wherein component (D) comprises gamma-butyrolactone.
7. The mass ratio of component (B) to component (D) [(D) / (B)] is 3 x 10 -4 Above 1200 x 10 -4 The oral composition according to claim 5 or 6, wherein:
8. The oral composition according to any one of claims 5 to 7, wherein the mass ratio of component (C) to component (D) [(D) / (C)] is 0.1 to 50.
9. The oral composition according to any one of claims 1 to 8, which is a solid oral composition.
10. The oral composition according to any one of claims 1 to 8, which is a liquid oral composition.
